ELR Positive CXCL Chemokines Are Highly Expressed in an Animal Model of Ulcerative Colitis

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2019 Aug 17

PMID 31417300

Citations 18

Authors

Mohammad Amin Boshagh

Poorya Foroutan

Mohammad Raman Moloudi

Shohreh Fakhari

Parisa Malakouti

Bahram Nikkhoo

Ali Jalili

Affiliations

Soon will be listed here.

Abstract

The presence of neutrophil-rich inflammation in colon tissues of patients with ulcerative colitis (UC) is one of the most important histological characteristics of this disease. However, the expression of CXCL chemokines governing the infiltration of neutrophils in UC has not been well elucidated. In this experimental study, the UC model was induced in Wistar rats by administration of 2 mL 4% acetic acid into the large colon through the rectum. Animals were anesthetized after 48 hrs; their colon tissue samples were isolated for macroscopic and histopathological examinations. The expression of CXCL family was assessed by reverse transcription polymerase chain reaction (qRT-PCR) technique. Heavy infiltration of neutrophils, coagulation necrosis, and ulcers were observed in H&E staining, which pathologically proved the UC model. qRT-PCR results showed that ELR CXC chemokines such as CXCL6 and CXCL3 had the highest expression in the UC group, which was 49 and 28 times higher than that of the control group, respectively. In addition, other chemokines of this group including CXCL1, CXCL2, and CXCL7 had a significant increase compared to the control group (P≤0.05). However, ELR CXC chemokines such as CXCL4, CXCL13, and CXCL16 showed a smaller upregulation, while CXCL14 chemokine showed a significant decrease compared to the control group (P≤0.05). However, the expression of CXCL9-12 and CXCL17 did not change. The results showed that the ELR CXC chemokines, especially CXCL6 and CXCL3, many involved in the pathogenesis of UC; therefore, CXCL6 and CXCL3 chemokines can be used as therapeutic targets for UC, although more studies using human samples are required.

Citing Articles

Bone marrow mesenchymal stromal cells support regeneration of intestinal damage in a colitis mouse model, independent of their CXCR4 expression.

Pervin B, Gizer M, Seker M, Erol O, Gur S, Polat E Clin Transl Sci. 2024; 17(5):e13821.

PMID: 38742709 PMC: 11092303. DOI: 10.1111/cts.13821.

CXCL14 and miR-4484 serves as potential salivary biomarkers for early detection of peri-implantitis.

Urvasizoglu G, Kilic A, Capik O, Gundogdu M, Karatas O Odontology. 2023; 112(3):864-871.

PMID: 38087011 DOI: 10.1007/s10266-023-00876-z.

Tratt Fruit Extract Prevents Dss-Induced Ulcerative Colitis in Mice by Modulating the Gut Microbiota and the IL-17 Signaling Pathway.

Li X, Ling Y, Huang X, Zhou T, Wu S, Zhang S Nutrients. 2023; 15(21).

PMID: 37960213 PMC: 10650662. DOI: 10.3390/nu15214560.

CXCL6: A potential therapeutic target for inflammation and cancer.

Dai C, Yang H, Liu Q, Rahman K, Zhang H Clin Exp Med. 2023; 23(8):4413-4427.

PMID: 37612429 DOI: 10.1007/s10238-023-01152-8.

Identification of diagnostic biomarks and immune cell infiltration in ulcerative colitis.

Chen Q, Bei S, Zhang Z, Wang X, Zhu Y Sci Rep. 2023; 13(1):6081.

PMID: 37055577 PMC: 10102327. DOI: 10.1038/s41598-023-33388-5.

References

Bernstein C, Blanchard J, Rawsthorne P, Wajda A . Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999; 149(10):916-24. DOI: 10.1093/oxfordjournals.aje.a009735. View

Uguccioni M, Gionchetti P, Robbiani D, Rizzello F, Peruzzo S, Campieri M . Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999; 155(2):331-6. PMC: 1866859. DOI: 10.1016/S0002-9440(10)65128-0. View

Yeung M, Melgar S, Baranov V, Oberg A, Danielsson A, Hammarstrom S . Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gammadelta expression. Gut. 2000; 47(2):215-27. PMC: 1728017. DOI: 10.1136/gut.47.2.215. View

Dwinell M, Lugering N, Eckmann L, Kagnoff M . Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology. 2001; 120(1):49-59. DOI: 10.1053/gast.2001.20914. View

Cole A, Ganz T, Liese A, Burdick M, Liu L, Strieter R . Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol. 2001; 167(2):623-7. DOI: 10.4049/jimmunol.167.2.623. View

Ohtsuka Y, Lee J, Stamm D, Sanderson I . MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Gut. 2001; 49(4):526-33. PMC: 1728474. DOI: 10.1136/gut.49.4.526. View

Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B . Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001; 194(6):855-61. PMC: 2195966. DOI: 10.1084/jem.194.6.855. View

Kucharzik T, Walsh S, Chen J, Parkos C, Nusrat A . Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001; 159(6):2001-9. PMC: 1850599. DOI: 10.1016/S0002-9440(10)63051-9. View

Carlsen H, Baekkevold E, Johansen F, Haraldsen G, Brandtzaeg P . B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue. Gut. 2002; 51(3):364-71. PMC: 1773345. DOI: 10.1136/gut.51.3.364. View

10.

Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A . Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res. 2002; 22(10):1067-8. DOI: 10.1089/107999002760624305. View

11.

Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U . Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 2002; 441(5):500-13. DOI: 10.1007/s00428-002-0684-z. View

12.

Banks C, Bateman A, Payne R, Johnson P, Sheron N . Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol. 2002; 199(1):28-35. DOI: 10.1002/path.1245. View

13.

Strieter R, Kunkel S, Burdick M, Lincoln P, Walz A . The detection of a novel neutrophil-activating peptide (ENA-78) using a sensitive ELISA. Immunol Invest. 1992; 21(6):589-96. DOI: 10.3109/08820139209069393. View

14.

Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P . CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol. 2004; 34(7):1992-2000. DOI: 10.1002/eji.200324807. View

15.

Hanauer S . Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2005; 12 Suppl 1:S3-9. DOI: 10.1097/01.mib.0000195385.19268.68. View

16.

Walz A, Burgener R, Car B, Baggiolini M, Kunkel S, Strieter R . Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991; 174(6):1355-62. PMC: 2119025. DOI: 10.1084/jem.174.6.1355. View

17.

Egesten A, Eliasson M, Olin A, Erjefalt J, Bjartell A, Sangfelt P . The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis. 2007; 22(12):1421-7. DOI: 10.1007/s00384-007-0370-3. View

18.

Lacher M, Kappler R, Berkholz S, Baurecht H, von Schweinitz D, Koletzko S . Association of a CXCL9 polymorphism with pediatric Crohn's disease. Biochem Biophys Res Commun. 2007; 363(3):701-7. DOI: 10.1016/j.bbrc.2007.09.020. View

19.

Chin A, Parkos C . Pathobiology of neutrophil transepithelial migration: implications in mediating epithelial injury. Annu Rev Pathol. 2007; 2:111-43. DOI: 10.1146/annurev.pathol.2.010506.091944. View

20.

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View